Darryl Shaw
06-25-2011, 05:22 AM
The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomised trial in young overweight women.
Abstract
Background
The problems of adherence to energy restriction in humans are well known.
Objective
To compare the feasibility and effectiveness of IER with CER for weight loss, insulin sensitivity and other metabolic disease risk markers.
Design
Randomised comparison of a 25% energy restriction as IER (~2266 kJ/day for 2 days/week) or CER (~6276 kJ/day for 7 days/week) in 107 overweight or obese (mean [±SD] body mass index 30.6 [±5.1] kg/m2) premenopausal women over 6 months. Weight, anthropometry, biomarkers for breast cancer, diabetes, cardiovascular disease and dementia risk; insulin resistance (HOMA), oxidative stress markers, leptin, adiponectin, IGF-1 and IGF binding proteins 1 and 2, androgens, prolactin, inflammatory markers (high sensitivity C-reactive protein and sialic acid), lipids, blood pressure and brain derived neurotrophic factor were assessed at baseline and after 1, 3 and 6 months.
Results
Last observation carried forward analysis showed IER and CER are equally effective for weight loss, mean (95% confidence interval [CI]) weight change for IER was −6.4 (−7.9 to −4.8) kg vs.−5.6 (−6.9 to −4.4) kg for CER (P value for difference between groups = 0.4). Both groups experienced comparable reductions in leptin, free androgen index, high sensitivity C-reactive protein, total and LDL cholesterol, triglycerides, blood pressure and increases in sex hormone binding globulin, IGF binding proteins 1 and 2. Reductions in fasting insulin and insulin resistance were modest in both groups, but greater with IER than CER; difference between groups for fasting insulin −1.2 [−1.4 to −1.0] μU/ml, and insulin resistance −1.2 [−1.5 to −1.0] μU/mmol/L (both P=0.04).
Conclusion
IER is as effective as CER in regards to weight loss, insulin sensitivity and other health biomarkers and may be offered as an alternative equivalent to CER for weight loss and reducing disease risk.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017674/?tool=pubmed
Abstract
Background
The problems of adherence to energy restriction in humans are well known.
Objective
To compare the feasibility and effectiveness of IER with CER for weight loss, insulin sensitivity and other metabolic disease risk markers.
Design
Randomised comparison of a 25% energy restriction as IER (~2266 kJ/day for 2 days/week) or CER (~6276 kJ/day for 7 days/week) in 107 overweight or obese (mean [±SD] body mass index 30.6 [±5.1] kg/m2) premenopausal women over 6 months. Weight, anthropometry, biomarkers for breast cancer, diabetes, cardiovascular disease and dementia risk; insulin resistance (HOMA), oxidative stress markers, leptin, adiponectin, IGF-1 and IGF binding proteins 1 and 2, androgens, prolactin, inflammatory markers (high sensitivity C-reactive protein and sialic acid), lipids, blood pressure and brain derived neurotrophic factor were assessed at baseline and after 1, 3 and 6 months.
Results
Last observation carried forward analysis showed IER and CER are equally effective for weight loss, mean (95% confidence interval [CI]) weight change for IER was −6.4 (−7.9 to −4.8) kg vs.−5.6 (−6.9 to −4.4) kg for CER (P value for difference between groups = 0.4). Both groups experienced comparable reductions in leptin, free androgen index, high sensitivity C-reactive protein, total and LDL cholesterol, triglycerides, blood pressure and increases in sex hormone binding globulin, IGF binding proteins 1 and 2. Reductions in fasting insulin and insulin resistance were modest in both groups, but greater with IER than CER; difference between groups for fasting insulin −1.2 [−1.4 to −1.0] μU/ml, and insulin resistance −1.2 [−1.5 to −1.0] μU/mmol/L (both P=0.04).
Conclusion
IER is as effective as CER in regards to weight loss, insulin sensitivity and other health biomarkers and may be offered as an alternative equivalent to CER for weight loss and reducing disease risk.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017674/?tool=pubmed